“
“OBJECTIVES: The aim of this study was to investigate whether MK-8776 mw rosuvastatin affects expression and activity of rat CYP2C6. This cytochrome P450 is considered to be a counterpart of human CYP2C9, which metabolizes many drugs, including diclofenac, ibuprofen or warfarin.\n\nDESIGN: Male hereditary hypertriglyceridemic (HHTg) rats were fed standard laboratory diet (STD) or high cholesterol diet (HCD: STD + 1% of cholesterol w/w + 10% of lard fat w/w) for 21 days. A third group of rats were fed high a cholesterol diet with rosuvastatin added (0.03% w/w). Expression of CYP2C6 was measured in liver samples using real-time PCR (mRNA level) and Western blotting (protein

level). Formation of diclofenac metabolites (typical enzyme activity of CYP2C6) was analyzed using HPLC with UV detection.\n\nRESULTS: Administration of rosuvastatin to HHTg rats resulted in significantly increased mRNA expression and enzyme activity in HCD-fed animals; changes of CYP2C6 protein were non-significant. These results suggest that CYP2C6 expression and activity are positively affected by rosuvastatin in hereditary hypertriglyceridemic rats

after intake of HCD.\n\nCONCLUSION: The results presented open the possibility that in humans, rosuvastatin may affect the metabolism of many drugs by influencing expression and activity of CYP2C6 (counterpart of AS1842856 cost human CYP2C9). Further studies are needed to elucidate the effects of this statin on CYP2C9 in humans.”
“Two new steroidal glycosides

were isolated by fractionation of total extracted substances from inflorescences and flower stalks of Allium rotundum (Alliaceae). The structures were determined on the basis of chemical transformations, physical constants, and spectral ABT-263 mouse data as 26-O-beta-D-glucopyranosyl-(25R)-5 alpha-furostan-2 alpha,3 beta,22 alpha,26-tetraol 3-O-beta-D-glucopyranosyl-(1 -> 2)[beta-D-xylopyranosyl-(1 -> 3)]-beta-D-glucopyranosyl-(1 -> 4)-beta-D-galactopyranoside (2) and (25R)-5 alpha-spirostan-2 alpha,3 beta-diol 3-O-beta-D-glucopyranosyl-(1 -> 3)-beta-D-glucopyranosyl-(1 -> 2)-[beta-D-xylopyranosyl-(1 -> 3)]-beta-D-glucopyranosyl-(1 -> 4)-beta-D-galactopyranoside (3).”
“The modular endoglucanase Cel9B from Paenibacillus barcinonensis is a highly efficient biocatalyst, which expedites pulp refining and reduces the associated energy costs as a result. In this work, we set out to identify the specific structural domain or domains responsible for the action of this enzyme on cellulose fibre surfaces with a view to facilitating the development of new cellulases for optimum biorefining. Using the recombinant enzymes GH9-CBD3c, Fn3-CBD3b, and CBD3b, which are truncated forms of Cel9B, allowed us to assess the individual effects of the catalytic, cellulose binding, and fibronectin-like domains of the enzyme on the refining of TCF kraft pulp from Eucalyptus globulus.